Fig 1.
Flow diagram of patient selection.
Table 1.
Patient characteristics stratified by TP53 and CDKN2A mutations.
Fig 2.
Time-to-progression by mutation status.
Table 2.
Time to progression by mutation.
Fig 3.
Overall survival by mutation status.
Table 3.
Overall survival from metastatic diagnosis by mutation.